Showing results (121-130 of 969) with videos related to
Sort By:
Pageof 97
Leukemia & Lymphoma|August 19, 2025
Mortality and relapse dynamics in AML after three years of complete remissionSamuel Urrutia, Wei-Ying Jen, Koji Sasaki, et al.Cancer|August 11, 2016
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phaseKoichi Takahashi, Hagop M Kantarjian, Yulong Yang, et al.Cancer|October 20, 2015
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Preetesh Jain, et al.American Journal of Hematology|December 23, 2014
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndromePaolo Strati, Hagop Kantarjian, Farhad Ravandi, et al.Blood Advances|November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLGhayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.JCO Oncology Practice|July 16, 2024
Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisFadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.Journal of Hematology & Oncology|January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposureNicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.Critical Reviews in Oncology/Hematology|July 13, 2016
Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?Aziz Nazha, Joseph D Khoury, Srdan Verstovsek, et al.Expert Opinion on Pharmacotherapy|May 8, 2020
The pharmacological management of hairy cell leukemiaJorge Ramos Perez, Farhad Ravandi-KashaniBlood Cancer Journal|July 1, 2021
Acute promyelocytic leukemia current treatment algorithmsMusa Yilmaz, Hagop Kantarjian, Farhad RavandiPageof 97